Replacement of antipsychotic and antiepileptic medication by L-α-methyldopa in a woman with velocardiofacial syndrome

International Clinical Psychopharmacology

Volumn 18, Issue 2, 2003, Pages 117-119

  O'Hanlon, James F ^a   Ritchie, Rand C ^b   Smith, Edward A ^c   Patel, Rashiklal ^b  

^a Tri Counties Reg Cancer Registry   (United States)

^b Private Practice   (United States)

^c Priv Pract Neurosurg/Neurology   (United States)

Author keywords

Alpha methyldopa; Case study; Catecholamine O methyltransferase; Dopamine; Mania; Noradrenaline; Norepinephrine; Psychosis; Velo cardiofacial syndrome

Indexed keywords

ANTICONVULSIVE AGENT; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; CITALOPRAM; HALOPERIDOL; METHYLDOPA; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; QUETIAPINE; THIORIDAZINE; TIOTIXENE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; FALLOT TETRALOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GALACTORRHEA; HALLUCINATION; HUMAN; HYPERTENSION; MENTAL FUNCTION; NEUROTRANSMISSION; NEUROTRANSMITTER UPTAKE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; RESIDENTIAL CARE; SEIZURE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VELOCARDIOFACIAL SYNDROME;

ABNORMALITIES, MULTIPLE; ADRENERGIC ALPHA-AGONISTS; ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CRANIOFACIAL ABNORMALITIES; FEMALE; HUMANS; METHYLDOPA; PHENOTYPE; PSYCHOTIC DISORDERS; SEIZURES; SYNDROME;

EID: 0037346116     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200303000-00010     Document Type: Article

References (19)

1. Carlson C, Papolos D, Pandita RK, Faedda GL, Veit S, Goldberg R, et al. (1997) Molecular analysis of velo-cardio-facial syndrome patients with psychiatric disorders. Am J Hum Genet 60:851-859.
2. Chouinard G, Annable L (1976) Alpha-methyldopachlorpromazine combination in schizophrenic patients. Neuropsychobiology 2:118-126.
3. Chouinard G, Serrano PM, Tetreault L (1973) Potentiation of haloperidol by alpha-methyldopa in the treatment of schizophrenic patients. Curr Ther Clin Exp 15:473-483.
4. Choy VJ, Chalmers J (1984) Importance of central serotonin neurons in the hypotensive action of methyldopa in the rat. Clin Exp Pharmacol Physiol 11:37-44.
5. Day MD, Roach AG (1976) Cardiovascular effects of dopamine after central administration into conscious cats. Br J Pharmacol 58:505-515.
6. Dominic JA, Moore KE (1971) Depression of behavior and the brain content of alpha-methylnorepinephrine and alpha-methyldopamine following the administration of alpha-methyldopa. Neuropharmacology 10:33-44.
7. Forsyth RP, Bolme P, Ishizaki T, Melmon KL (1978) Hemodynamic effects of systemic and central administration of alpha-methyldopa. J Pharmacol Exp Ther 205:675-682.
8. Goldberg MR, Tung CS, Feldman RD, Smith HE, Oates JA, Robertson D (1982) Differential competition by L-alpha-methyldopa metabolites for adrenergic receptors in rat forebrain. J Pharmacol Exp Ther 220:552-560.
9. Gottlieb S, Emanuel BS, Driscoll DA, Sellinger B, Wang Z, Roe B, et al. (1997) George syndrome minimal critical region contains a goosecoid-like (GSCL) homeobox gene that is expressed early in human development. Am J Med Genet 60:1194-1201.
10. Hagerman RJ (1999) Neurodevelopmental disorders. New York: Oxford University Press; pp. 291-312.
11. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, et al. (1996) Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 67:468-472.
12. Morrow B, Carlson CG, Goldenberg R (1996) Psychiatric illness in children with velo-cardio-facial syndrome with/without 22q11 deletions. Am J Hum Genet 59(suppl):A89.
13. Murphy KC, Owen MJ (1998) The behavioral phenotype in velo-cardiofacial syndrome. J Med Genet 35(suppl):S17.
14. Oates JA, Brown NJ (2001) Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE (editors): Goodman and Gillman's the pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill; pp. 871-900.
15. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R, et al. (1996) Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?. Am J Psychiatry 153:1541-1547.
16. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, et al. (1994) Psychiatric illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 182:476-478.
17. Ruffolo RR, Goldberg MR, Morgan EL (1984) Interactions of epinephrine, norepinephrine, dopamine and their corresponding alpha-methyl-substituted derivatives with alpha and beta adrenoceptors on the pithed rat. J Pharmacol Exp Ther 205:675-682.
18. Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD, Argamaso RV, et al. (1978) A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning difficulties. Cleft Palate J 15:56-62.
19. Uretsky NJ, Chase GJ, Lorenzo AV (1975) Effect of alpha-methyldopa on dopamine synthesis and release in rat striatum in vitro. J Pharmacol Exp Ther 193:73-87.